We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 30. | 장 마감 후 (AMC) | $1.38 | — | — | $450.5M | — | 예정 |
| FY2026 Q1 | 2025. 03. 28. | 시각 미정 | — | $-0.66 | — | — | $437.39M | 보고됨 |
| FY2025 Q3 | 2024. 09. 27. | 시각 미정 | — | $2.46 | — | — | $1.27B |
Consensus PT $97.56 · 9 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 29. | Citigroup | — | 의견 유지 | Neutral → Neutral | — | Citigroup: Neutral |
| 2026. 05. 13. | Oppenheimer | — | 투자의견 상향 | Perform → Outperform | — | Oppenheimer: Perform → Outperform |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q2 | 2024. 06. 28. | 시각 미정 | — | $1.47 | — | — | $835.68M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Integer Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Costa Rica, Puerto Rico, Ireland, and internationally. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; implanted medical devices, implanted leads, procedure accessories, and external devices; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; orthopedics, minimally invasive surgery, and general surgery devices; and portable medical devices, including patient monitoring, ventilators, portable defibrillators, portable ultrasound, and X-Ray machines. Furthermore, the company provides medical technologies; supplies medical stamped components, and shallow and deep draw casings and assemblies; and epicardial pacing leads. It serves multi-national original equipment manufacturers and affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, cardio and vascular, and advanced surgical and portable medical markets. The company provides its products under the Greatbatch Medical and the Lake Region Medical brands. The company was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
Stored first · Google News · Yahoo Finance (English)
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Integer Holdings Corporation (ITGR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Integer Holdings Corporation (ITGR) and Encourages Stockholders to Learn More About the Investigation ACCESS Newswire
1 Healthcare Stock with Promising Prospects and 2 We Find Risky
Integer Holdings Corporation (ITGR) Stock Analysis: Potential Upside and Strong Buy Ratings in the Medical Device Sector - DirectorsTalk Interviews
Integer Holdings Corporation (ITGR) Stock Analysis: Potential Upside and Strong Buy Ratings in the Medical Device Sector DirectorsTalk Interviews
Citi Maintains Integer Holdings(ITGR.US) With Hold Rating, Raises Target Price to $92 - Moomoo
Citi Maintains Integer Holdings(ITGR.US) With Hold Rating, Raises Target Price to $92 Moomoo
Cellula Robotics, Integer Technologies to Advance Adaptive Mission Assurance for Multi-Vehicle Undersea Operations - Marine Technology News
Cellula Robotics, Integer Technologies to Advance Adaptive Mission Assurance for Multi-Vehicle Undersea Operations Marine Technology News
Integer Holdings Enhances Executive Protections Amid Strategic Review - The Globe and Mail
Integer Holdings Enhances Executive Protections Amid Strategic Review The Globe and Mail